ストックスクリーナーアプリを入手
1.35
2.19%
-0.02
アフターアワーズ：
1.36
0.01
+0.74%
前日終値:
$1.37
開ける：
$1.39
24時間の取引高:
52,565
Relative Volume:
0.36
時価総額：
$21.48M
収益：
$345.00K
当期純損益:
$-11.25M
株価収益率:
-1.8706
EPS:
-0.7217
ネットキャッシュフロー:
$-16.70M
1週間 パフォーマンス:
-4.96%
1か月 パフォーマンス:
+12.61%
6か月 パフォーマンス:
+61.45%
1年 パフォーマンス:
+39.87%
1日の値動き範囲:
$1.31
$1.39
1週間の範囲:
$1.255
$1.55
52週間の値動き範囲:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.35 | 21.80M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc (ALLR) 最新ニュース
Allarity Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Investing News Network
Allarity Therapeutics Q2 EPS of $(0.21) beats $(0.25) estimate - scanx.trade
Allarity Therapeutics reports Q2 results, cash position - Investing.com
Allarity Therapeutics, Inc. 2026: Revenue $0 Net income ($3.41M), EPS ($0.21) — 10-Q Summary - TradingView
Allarity Therapeutics reports Q2 results, cash position By Investing.com - Investing.com Canada
Allarity Therapeutics (ALLR) adds $20M debt, holds $26.9M cash in Q2 2026 - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready ... - Caledonian Record
Allarity Therapeutics Reports Second Quarter 2026 Results - GlobeNewswire
Allarity Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneDividend ETF - dars.gov.et
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
Allarity Therapeutics Inc (ALLR) Income Statement - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190|Chg%:-0.030 - TradingKey
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Allarity Therapeutics Inc (ALLR) News, Articles, Events & Latest Updates - Stocktwits
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
Update on One NASDAQ- Listed Pharmaceutical Stock– Allarity Therapeutics Inc - Kalkine
Allarity Therapeutics (ALLR) Edges Higher as Stock Tests Narrow Trading RangeTRIN Signal - dars.gov.et
Allarity Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Biotech Focuses on Pipeline ExecutionEstimate Accuracy - dars.gov.et
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics (ALLR) Tests Support After 2.92% Decline – Key Levels Under ScrutinyMean Reversion Trade - dars.gov.et
Allarity Therapeutics (ALLR) Faces Continued Pressure, Testing Key Support at $1.11Passive Flow - dars.gov.et
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Allarity Therapeutics Obtains CLIA Certification For In-House DRP Testing And Advances Stenoparib Toward FDA Registration - marketscreener.com
Allarity Therapeutics obtains CLIA lab certification - Investing.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
Allarity Therapeutics obtains CLIA lab certification By Investing.com - Investing.com Nigeria
Allarity’s Denmark lab gets CLIA status for U.S. cancer-trial testing - Stock Titan
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Offset Investor ConcernsAnalyst Earnings Estimate - DonanımHaber
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year? - NewsBreak: Local News & Alerts
Allarity Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesSubscription Growth Report - dars.gov.et
Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com
Allarity receives U.S. patent for stenoparib diagnostic test By Investing.com - Investing.com Nigeria
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - Yahoo Finance
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
2.67%
0.04%
大文字化:
|
ボリューム (24 時間):